Empagliflozin Intermediate

Empagliflozin Intermediate

Acetyl Empagliflozin ( CAS # 915095- 99- 7 )
Iodinated Empagliflozin Intermediate ( CAS # 915095- 94- 2 )
Brominated Empagliflozin Intermediate ( CAS # 915095- 89- 5 )

White to off-white crystalline powder

Purity ≥ 98.0% ( by HPLC )

Empagliflozin is a highly selective sodium-glucose co-transporter-2 ( SGLT2 ) inhibitor indicated for the management of several chronic conditions:

Type 2 Diabetes Mellitus:
Empagliflozin improves glycemic control in adults with type 2 diabetes by inhibiting SGLT2 in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion.
It is used:
As monotherapy when metformin is inappropriate due to intolerance or contraindications.
As part of combination therapy with other antidiabetic agents (such as metformin, sulfonylureas, DPP-4 inhibitors, or insulin) to achieve target blood glucose levels.
To provide additional cardiovascular benefits beyond glycemic control.

Heart Failure with Reduced Ejection Fraction (HFrEF):
Empagliflozin significantly reduces the risk of cardiovascular death and hospitalization for heart failure in adults with symptomatic HFrEF, regardless of the presence of diabetes.
Clinical trials ( such as EMPEROR-Reduced ) have shown improved outcomes in mortality and morbidity among patients treated with empagliflozin.

Chronic Kidney Disease (CKD):
Empagliflozin is also indicated to slow the progression of kidney disease, reduce the risk of end-stage kidney disease, and decrease cardiovascular death in adults with CKD at risk of disease progression.
It demonstrates renal protective effects independent of glycemic control.

Cardiovascular Risk Reduction:
In patients with type 2 diabetes and established cardiovascular disease, empagliflozin reduces the risk of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, as demonstrated in the EMPA-REG OUTCOME trial.

Mechanism of Action:
By reducing blood glucose levels independently of insulin pathways, empagliflozin offers a low risk of hypoglycemia and contributes to weight loss and modest blood pressure reduction.

Conforms to USP and EP.

Store at - 20°C or below in a tightly closed container.
Protect from moisture, light, and high temperatures.
Maintain under an inert gas atmosphere if necessary.

Hot Tags: empagliflozin intermediate, China empagliflozin intermediate manufacturers, suppliers, 6-APA, 2-Nitrobenzaldehyde, Ethyl 8 bromooctanoate, pharmaceutical intermediates, 3-Benzoxazine-2, MICA